Epstein-Barr Virus (EBV), IgA, Serum
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
The test is indicated for patients with malignant lesions of type 2 and 3 in whom nasopharyngeal carcinoma is suspected; eg, patients with metastases to the cervical lymph nodes from an unknown primary source.
Immunofluorescence Assay (IFA)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Epstein-Barr Virus (EBV), IgA, S
EBV (Epstein-Barr Virus), IgA
EPSTEIN BARR IGA(S)
IgA Virus Antibody
EPSTEIN BARR IGA(S)
IgA Virus Antibody
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 0.2 mL
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross reject
Mild OK; Gross reject
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Serum||Refrigerated (preferred)||14 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Infection with Epstein-Barr virus (EBV) usually occurs early in life. For several weeks to months after acute onset of the infection, it is spread by upper respiratory secretions that contain the virus.
Among the clinical disorders due to EBV infections, infectious mononucleosis (IM) is most common. Other disorders due to EBV infection have been recognized for several years, including African-type Burkitt's lymphoma and nasopharyngeal carcinoma (NPC). The World Health Organization (WHO) classifies NPC as type 1 (keratinizing squamous cell carcinoma), type 2 (nonkeratinizing squamous cell carcinoma), and type 3 (undifferentiated carcinoma).
EBV infection also may cause lymphoproliferative syndromes, especially in patients who have undergone renal or bone marrow transplantation and in those who have AIDS.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Presence of IgA class antibody to the viral capsid antigen (VCA) of Epstein-Barr virus (EBV) indicates active replication of EBV.
High levels of IgA class antibody to the VCA supports the clinical diagnosis of nasopharyngeal carcinoma (NPC). These antibodies are present in 84% of patients with type 2 NPC.
IgA directed against VCA is positive for type 1 carcinoma in only 16% of cases.
The specificity of the test is such that 82% to 91% of healthy blood donors and patients who do not have NPC have negative responses.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
It should be noted that there are some patients with nasopharyngeal carcinoma whose serum will contain antibodies to the early antigen (EBVE/56104 Epstein-Barr Virus [EBV] IgG Antibody to Early Antigen, Serum) of the virus but not antibodies to the viral capsid antigen and vice versa.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Liu MT, Cy Y: Prognostic value of anti-Epstein-Barr Virus antibodies in nasopharyngeal carcinoma (NPC). Radiat Med 1998;16:113-117
2. Puthavathana P, Kositanont U, Chongkolwantana C, et al: Prevalence of IgA specific antibodies to Epstein-Barr Virus capsid and early antigens in nasopharyngeal carcinoma. Asian Pac J Allergy Immonol 1993;11:39-43
Method Description Describes how the test is performed and provides a method-specific reference
Epstein-Barr virus-infected substrate cells are reacted with dilutions of serum from the patient. IgA antibodies present in the serum that react with the viral capsid antigen expressed in the infected cells are measured by the indirect immunofluorescence test.(Neel HB 3d, Pearson GR, Taylor WF: Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma and in comparison groups. Ann Otol Rhinol Laryngol 1984;93:477-482)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Wednesday; 9 a.m.
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|
|8891||Epstein-Barr Virus (EBV), IgA, S||In Process|